Rick Scalzo
Finanzdirektor/CFO bei DYNE THERAPEUTICS, INC.
Vermögen: 4 Mio $ am 31.05.2024
Profil
Rick Scalzo's current job is Senior Vice President-Finance & Administration at Dyne Therapeutics, Inc. His former jobs include being a Controller at Astellas Institute for Regenerative Medicine in 2014, Chief Accounting Officer at Kaleido Biosciences, Inc. in 2019, and Controller at X4 Pharmaceuticals, Inc. from 2016 to 2018.
He completed his undergraduate degree at Boston College in 2008 and earned an MBA from the University of Massachusetts in 2016.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
DYNE THERAPEUTICS INC
0,12% | 11.06.2024 | 113 774 ( 0,12% ) | 4 Mio $ | 31.05.2024 |
Aktive Positionen von Rick Scalzo
| Unternehmen | Position | Beginn |
|---|---|---|
| DYNE THERAPEUTICS, INC. | Finanzdirektor/CFO | 01.07.2020 |
Ehemalige bekannte Positionen von Rick Scalzo
| Unternehmen | Position | Ende |
|---|---|---|
| KALEIDO BIOSCIENCES, INC. | Comptroller/Controller/Auditor | 29.11.2019 |
| X4 PHARMACEUTICALS, INC. | Comptroller/Controller/Auditor | 01.08.2018 |
| OCATA THERAPEUTICS INC | Comptroller/Controller/Auditor | 01.09.2014 |
Ausbildung von Rick Scalzo
| University of Massachusetts | Masters Business Admin |
| Boston College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| KALEIDO BIOSCIENCES, INC. | Health Technology |
| X4 PHARMACEUTICALS, INC. | Health Technology |
| DYNE THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Astellas Institute for Regenerative Medicine
 Astellas Institute for Regenerative Medicine Pharmaceuticals: MajorHealth Technology Astellas Institute for Regenerative Medicine engages in the development and commercialization of human pluripotent stem cell technology in the field of regenerative medicine. The company also have a preclinical development pipeline in areas outside of ophthalmology, including; autoimmune diseases, inflammatory diseases, and wound healing. The company was founded on May 18, 2000 and is headquartered in Marlborough, MA. | Health Technology |
